J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

Data Compilation
#PharmaFlow

Pipeline Prospector May 2025: Pfizer strikes US$ 6 bn oncology pact; Lilly diversifies pipeline with US$ 2.3 bn in deals

Stock Recap
#PipelineProspector

Oraxim

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

68 API Suppliers, 39 USDMF, 21 CEP/COS, 9 EU WC, 22 KDMF, 4 NDC API, 16 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

254 FDF Dossiers, 34 FDA Orange Book, 112 Europe, 7 Canada, 8 South Africa, 93 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FOR SUSPENSION;ORAL - EQ 125MG BASE/5ML, FOR SUSPENSION;ORAL - EQ 250MG BASE/5ML

RELATED EXCIPIENT COMPANIES

3 Evonik, 4 Rochem International Inc, 20 SPI Pharma, 9 DKSH, 1 Pharm-RX Chemical, 5 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 ACG Worldwide, 8 Actylis, 2 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 19 BASF, 2 Clariant, 12 Corel Pharma Chem, 3 DFE Pharma, 1 Esteem Industries, 2 Finar, 9 Gangwal Chemicals, 8 Ideal Cures, 4 Ingredion Pharma Solutions, 17 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 14 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 20 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 4 Silverline Chemicals, 2 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus

EXCIPIENTS BY APPLICATIONS

62 Fillers, Diluents & Binders, 55 Coating Systems & Additives, 30 Direct Compression, 30 Controlled & Modified Release, 29 Thickeners and Stabilizers, 26 Lubricants & Glidants, 24 Solubilizers, 23 Taste Masking, 21 Co-Processed Excipients, 21 Disintegrants & Superdisintegrants, 21 Topical, 19 Granulation, 19 Chewable & Orodispersible Aids, 16 Parenteral, 15 Film Formers & Plasticizers, 10 Emulsifying Agents, 9 Rheology Modifiers, 7 API Stability Enhancers, 5 Empty Capsules, 5 Surfactant & Foaming Agents, 4 Vegetarian Capsules, 4 Coloring Agents

DIGITAL CONTENT

11 News #PharmaBuzz

11 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 112 Regulatory FDF Prices

MARKET PLACE

26 APIs, 30 FDF Dossiers

PATENTS & EXCLUSIVITIES

9 Health Canada Patents

9 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 1 USP, 5 Others

ANALYTICAL

2 BioAnalytical Methods

2 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
28/06/2025	Unimark Remedies	India	UNIMARK REMEDIES LTD	20545	CEFUROXIME AXETIL USP	2007-05-23	Active	II	N/A
28/06/2025	ACS DOBFAR SPA	Italy	ACS DOBFAR SPA	10154	CEFUROXIME ACID	1991-03-01	Active	II	N/A

Oraxim

Oraxim

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

68 API Suppliers

39 USDMF

21 CEP/COS

9 EU WC

22 KDMF

4 NDC API

16 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

254 FDF Dossiers

34 FDA Orange Book

112 Europe

7 Canada

8 South Africa

93 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FOR SUSPENSION;ORAL - EQ 125MG BASE/5ML

FOR SUSPENSION;ORAL - EQ 250MG BASE/5ML

RELATED EXCIPIENT COMPANIES

3 Evonik

4 Rochem International Inc

20 SPI Pharma

9 DKSH

1 Pharm-RX Chemical

5 Faran Shimi Pharmaceutical

3 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

2 Pfanstiehl

1 ACG Worldwide

8 Actylis

2 Aeon Procare

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Avesta Pharma

19 BASF

2 Clariant

12 Corel Pharma Chem

3 DFE Pharma

1 Esteem Industries

2 Finar

9 Gangwal Chemicals

8 Ideal Cures

4 Ingredion Pharma Solutions

17 Kerry

3 Kima Chemical

6 Lonza Capsugel

14 Microlex e.U

1 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

1 Novo Excipients

1 Pharmatrans-Sanaq

5 Pluviaendo

3 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

1 Qualicaps

20 Roquette

14 Seppic

8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

10 Sigachi Industries

4 Silverline Chemicals

2 The Dow Chemical Company

1 Ulanqab Kema New Material

1 Valens Pharmachem

4 Vasa Pharmachem

1 Vertellus

TABLET;ORAL - EQ 125MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 250MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 500MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons